For tube 1 of the EF AML/MDS panel, the first principal component (PC1, x-axis) showed the major contributions of the SSC (19%) and FSC (17%) parameters, whereas the second principal component (PC2, y-axis) showed the major contributions of HLA-DR (44%), CD34 (19%), and CD13 (10%) for the separation of the t(15;17) AML group from normal neutrophil-committed HPCs and all other AML groups. The gene discussed is CD34; the disease is acute myeloid leukemia.